What will be the greatest limitation(s) in the COVID19 vaccine rollout in the US?
Patient ability to navigate the entire process: 26.32%
Patient acceptance of vaccine: 21.05%
Distribution/Administration: 21.05%
Vaccine supply: 15.79%
Procedural differences from state to state: 10.53%
Systems used to set up vaccination appointments: 5.26%
Proper interpretation of the rules for each phase: 0.00%
How soon will states begin imposing new regulations on PBMs subsequent to the Supreme Court ruling in Rutledge v PCMA?
Q1 2021: 12.5%
Q2 2021: 0%
Q3 2021: 12.5%
Q4 2021: 12.5%
How will Amazon Pharmacy impact the pharmacy market in the next 5 years?
Competitive force influencing incumbents: 66.7%
Disruptive force: 25%
Market participant, no disruption: 8.3%
No longer participating: 0%
How will hospital and insurance plan price transparency impact patient costs?
Patients won’t notice: 40%
No impact: 20%
Increase patient costs: 20%
Decrease patient costs: 20%
What change do you most expect to see in the 340B program in the next year?
Reduced drug sales at 340B prices: 60%
Legislative changes to 340B program: 20%
HRSA lawsuit challenging 340B sales limitations by manufacturers: 20%
Shifting drug sales to 340B supportive manufacturers: 0%
Many industry conferences have been cancelled or shifted online due to COVID-19. How are you staying connected to industry colleagues?
Scheduling regular calls or online meetings: 54.5%
Participating in virtual conferences: 9.1%
Social media: 9.1%
All of the above: 27.3%
None of the above: 0%
Would you be willing to participate in a Phase 3 trial of a potential Covid-19 vaccine?
Yes: 71%
No: 29%
COVID-19 testing by community pharmacists will likely help pave the way for pharmacy provider status under Medicare, what is the expected time-frame?
1 year: 0%
2 years: 75%
3 years: 0%
4 years or more: 25%
Never: 0%
What percent of drug manufacturers will increase production of drug products in the US?
0%: 0%
1-10%: 14%
11-20%: 43%
21-30%: 29%
More than 30%: 14%
When do you feel that a COVID-19 vaccine will become available?
Less than 12 months: 8.3%
12 to 18 months: 66.7%
18 to 24 months: 25.0%
More than 24 months: 0%
Never: 0%